Swedish Foundation for Strategic Research   Report issue

Foundation Phase 2 Phase 3
Founded: Stockholm Sweden (1994)

Organization Overview

First Clinical Trial
2010
NCT01197144
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Swedish Foundation for Strategic Research

Active Ingredients

Drugs in Phase 3 Trials (1)

oxygen (1 trial)

Drugs in Phase 2 Trials (1)

msc-ki-pl-204 (1 trial)

Drugs in Other Trials (2)

adalimumab (humira) (1 trial)

oat (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Coronary Syndrome (Phase 3)

Angina, Unstable (Phase 3)

Aphonia (Phase 2)

Dysphonia (Phase 2)

Hoarseness (Phase 2)

Infarction (Phase 3)

Myocardial Infarction (Phase 3)

ST Elevation Myocardial Infarction (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 4